Interim Results of The Medicines Company’s ORION-3 Study of Inclisiran Presented at NLA Scientific Sessions

Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session.